We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further...
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0025 | -0.3214607175 | 0.7777 | 0.81 | 0.754 | 229650 | 0.77845301 | CS |
4 | -0.3448 | -30.7857142857 | 1.12 | 1.335 | 0.7341 | 460567 | 0.86074916 | CS |
12 | -0.4748 | -37.984 | 1.25 | 1.56 | 0.7341 | 239062 | 1.00456963 | CS |
26 | -0.1159 | -13.0063965885 | 0.8911 | 1.56 | 0.7341 | 178772 | 1.03701329 | CS |
52 | -0.9348 | -54.6666666667 | 1.71 | 1.81 | 0.7341 | 141798 | 1.09825767 | CS |
156 | -16.8948 | -95.6129032258 | 17.67 | 19.285 | 0.7341 | 208533 | 3.94952062 | CS |
260 | -25.3248 | -97.0298850575 | 26.1 | 43.07 | 0.7341 | 216021 | 7.30814225 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions